TScan Therapeutics (NASDAQ:TCRX – Get Rating) is one of 281 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare TScan Therapeutics to related companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, dividends and institutional ownership. Analyst Recommendations […]